How failure allows us to continually innovate
After writing about how the design aspects of antibodies can affect clinical performance recently, a few fascinated readers wrote in asking if there were more examples they could learn from.
Sure there are, and so that simple question inspired five more examples.
They range from small to large biotech/pharma, both public and private – no one has dominance in innovation chops, after all.
In this latest review we look at examples from CAR-T cell therapies, antibodies, immunocytokines and even bispecifics – there’s a lot of cool science going under the hood that many casual observers simply do not realise.
What’s more, some of the selected improvements and changes may (or may not) lead to enhancement of clinical performance down the road, so it is important to pay attention to what’s going on relative to each niche rather than be surprised and caught unaware…
To learn more and get a heads up on our latest oncology insights and R&D analysis, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
